C. Hudis

1.2k total citations
59 papers, 801 citations indexed

About

C. Hudis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, C. Hudis has authored 59 papers receiving a total of 801 indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 19 papers in Cancer Research. Recurrent topics in C. Hudis's work include Cancer Treatment and Pharmacology (33 papers), HER2/EGFR in Cancer Research (22 papers) and Breast Cancer Treatment Studies (16 papers). C. Hudis is often cited by papers focused on Cancer Treatment and Pharmacology (33 papers), HER2/EGFR in Cancer Research (22 papers) and Breast Cancer Treatment Studies (16 papers). C. Hudis collaborates with scholars based in United States, Spain and South Africa. C. Hudis's co-authors include Larry Norton, Andrew D. Seidman, Debu Tripathy, Nancy T. Sklarin, José Baselga, J. Mendelsohn, I. Craig Henderson, Sharon A. Baughman, Christopher C. Benz and J. Moore and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

C. Hudis

56 papers receiving 768 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Hudis United States	13	632	214	204	186	100	59	801
K. Aogi Japan	13	535 0.8×	153 0.7×	214 1.0×	185 1.0×	131 1.3×	33	770
Saverio Danese Italy	16	408 0.6×	228 1.1×	199 1.0×	75 0.4×	114 1.1×	31	880
Yoshiaki Sagara Japan	14	356 0.6×	122 0.6×	221 1.1×	140 0.8×	120 1.2×	31	639
Daisuke Takabatake Japan	15	357 0.6×	188 0.9×	208 1.0×	145 0.8×	113 1.1×	45	688
Hyesil Seol South Korea	15	480 0.8×	264 1.2×	307 1.5×	207 1.1×	244 2.4×	34	853
Patricia Gómez Spain	8	486 0.8×	155 0.7×	257 1.3×	88 0.5×	182 1.8×	16	653
Claudia Andreetta Italy	16	517 0.8×	162 0.8×	296 1.5×	81 0.4×	205 2.0×	41	831
Fumikata Hara Japan	17	501 0.8×	182 0.9×	298 1.5×	130 0.7×	277 2.8×	82	883
Armando Orlandi Italy	17	519 0.8×	192 0.9×	248 1.2×	100 0.5×	248 2.5×	90	879
Merdol Ibrahim United Kingdom	15	469 0.7×	254 1.2×	275 1.3×	262 1.4×	146 1.5×	19	735

Countries citing papers authored by C. Hudis

Since Specialization

Citations

This map shows the geographic impact of C. Hudis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Hudis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Hudis more than expected).

Fields of papers citing papers by C. Hudis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Hudis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Hudis. The network helps show where C. Hudis may publish in the future.

Co-authorship network of co-authors of C. Hudis

This figure shows the co-authorship network connecting the top 25 collaborators of C. Hudis. A scholar is included among the top collaborators of C. Hudis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Hudis. C. Hudis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Iyengar, Neil M., Diana Lake, Ayca Gucalp, et al.. (2017). Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy. Annals of Oncology. 28. v81–v81. 1 indexed citations

Gucalp, Ayca, SM Tolaney, SJ Isakoff, et al.. (2011). TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC).. Journal of Clinical Oncology. 29(15_suppl). TPS122–TPS122. 4 indexed citations

Hudis, C., Robert C. Hermann, Grace Makari‐Judson, et al.. (2011). 5026 POSTER DISCUSSION Sorafenib (SOR) Plus Chemotherapy (CRx) for Treatment (tx) of Patients (pts) With HER2-negative Locally Advanced (adv) or Metastatic (met) Breast Cancer (BC) and Prior Bevacizumab (BEV): Subgroup Analysis of AC01B07. European Journal of Cancer. 47. S338–S338. 1 indexed citations

Jhaveri, Komal, Gary A. Ulaner, Maurizio Fazio, et al.. (2011). Standardized uptake value (SUV) by positron emission tomography/computed tomography (PET/CT) as a prognostic variable in metastatic breast cancer (MBC).. Journal of Clinical Oncology. 29(27_suppl). 3–3. 2 indexed citations

Sparano, J. A., James F. Caravelli, Swati Patil, et al.. (2010). Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC).. Journal of Clinical Oncology. 28(15_suppl). 1086–1086. 4 indexed citations

Fornier, Monica, A. Abbruzzi, Gabriella D’Andrea, et al.. (2010). Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study.. Journal of Clinical Oncology. 28(15_suppl). 1156–1156. 2 indexed citations

Kiess, Ana P., Kathleen M. Mahoney, Sujata Patil, et al.. (2010). Adjuvant Trastuzumab Reduces Locoregional Recurrence in Women who Undergo Breast Conservation Therapy for Node-Negative HER2-Positive Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 78(3). S98–S98. 1 indexed citations

Mallam, Divya, Shekhar Patil, Jamie M. Howard, et al.. (2010). Pathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study.. Journal of Clinical Oncology. 28(15_suppl). 1589–1589. 5 indexed citations

Broadwater, Gloria, Paula N. Friedman, D. A. Berry, et al.. (2009). Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840.. Cancer Research. 69(2_Supplement). 6046–6046. 1 indexed citations

10.

Conlin, Alison, C. Hudis, A M Bach, et al.. (2009). Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). 1006–1006. 23 indexed citations

11.

Dugan, Ute, et al.. (2008). A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study. Journal of Clinical Oncology. 26(15_suppl). 1101–1101. 6 indexed citations

12.

Dickler, Maura N., et al.. (2008). Dose-dense (dd) doxorubicin-cyclophosphamide (AC) X 4 and short-term changes in left ventricular ejection fraction (LVEF) alone or with bevacizumab (B) in patients (pts) with early stage breast cancer (BC). Journal of Clinical Oncology. 26(15_suppl). 637–637. 2 indexed citations

13.

Chlebowski, Rowan T., George L. Blackburn, M. Katherine Hoy, et al.. (2008). Survival analyses from the Women's Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome. Journal of Clinical Oncology. 26(15_suppl). 522–522. 34 indexed citations

14.

Modi, Shanu, S. Sugarman, A. Stopeck, et al.. (2008). Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1027–1027. 50 indexed citations

15.

Richardson, Sylvia, et al.. (2008). Tolerance of bevacizumab in an older patient population: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Journal of Clinical Oncology. 26(15_suppl). 9569–9569. 3 indexed citations

16.

Conlin, Alison, A. D. Seidman, Mary Ellen Moynahan, et al.. (2007). Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report. Journal of Clinical Oncology. 25(18_suppl). 1104–1104. 8 indexed citations

17.

Fornier, Monica, Azeez Farooki, Cherry L. Estilo, et al.. (2007). 2104 POSTER Serum Levels of N-telopeptide (sNTX) and bone-specific alkaline phosphatase (BAP) in oncology patients (pts) who developed osteonecrosis of the jaw (ONJ) during therapy with intravenous bisphosphonates (IB). European Journal of Cancer Supplements. 5(4). 214–215. 1 indexed citations

18.

Berry, D. A., C. Cirrincione, R. B. Livingston, et al.. (2005). Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG. Journal of Clinical Oncology. 23(16_suppl). 620–620. 11 indexed citations

19.

Baselga, José, Debu Tripathy, J. Mendelsohn, et al.. (1999). Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.. PubMed. 26(4 Suppl 12). 78–83. 229 indexed citations

20.

Hudis, C., Andrew D. Seidman, John Crown, et al.. (1996). Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.. Journal of Clinical Oncology. 14(1). 58–65. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact